Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers - PubMed (original) (raw)
Review
. 2007 Feb;167(2):127-45.
doi: 10.1667/rr0719.1.
Affiliations
- PMID: 17390721
- DOI: 10.1667/rr0719.1
Free article
Review
Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers
Anna S E Ljungkvist et al. Radiat Res. 2007 Feb.
Free article
Abstract
Hypoxic cells are common in tumors and contribute to malignant progression, distant metastasis and resistance to radiotherapy. It is well known that tumors are heterogeneous with respect to the levels and duration of hypoxia. Several strategies, including high-oxygen-content gas breathing, radiosensitizers and hypoxic cytotoxins, have been developed to overcome hypoxia-mediated radioresistance. However, with these strategies, an increased tumor control rate is often accompanied by more severe side effects. Consequently, development of assays for prediction of tumor response and early monitoring of treatment responses could reduce both over- and undertreatment, thereby avoiding unnecessary side effects. The purpose of this review is to discuss different assays for measurement of hypoxia that can be used to detect changes in oxygen tension. The main focus is on exogenous bioreductive hypoxia markers (2-nitroimidazoles) such as pimonidazole, CCI-103F, EF5 and F-misonidazole. These are specifically reduced and bind to macromolecules in viable hypoxic cells. A number of these bioreductive drugs are approved for clinical use and can be detected with methods ranging from noninvasive PET imaging (low resolution) to microscopic imaging of tumor sections (high resolution). If the latter are stained for multiple markers, hypoxia can be analyzed in relation to different microenvironmental parameters such as vasculature, proliferation and endogenous hypoxia-related markers, for instance HIF1alpha and CA-IX. In addition, temporal and spatial changes in hypoxia can be analyzed by consecutive injection of two different hypoxia markers. Therefore, bioreductive exogenous hypoxia markers are promising as tools for development of predictive assays or as tools for early treatment monitoring and validation of potential endogenous hypoxia markers.
Similar articles
- Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.
Bussink J, Kaanders JH, van der Kogel AJ. Bussink J, et al. Radiother Oncol. 2003 Apr;67(1):3-15. doi: 10.1016/s0167-8140(03)00011-2. Radiother Oncol. 2003. PMID: 12758235 Review. - Changes in tumor hypoxia measured with a double hypoxic marker technique.
Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Ljungkvist AS, et al. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1529-38. doi: 10.1016/s0360-3016(00)00787-2. Int J Radiat Oncol Biol Phys. 2000. PMID: 11121659 - Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, van der Kogel AJ, Boerman OC, Bussink J. Troost EG, et al. Radiother Oncol. 2006 Aug;80(2):157-64. doi: 10.1016/j.radonc.2006.07.023. Epub 2006 Aug 14. Radiother Oncol. 2006. PMID: 16905213 - The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ, Kaanders JH. Jonathan RA, et al. Radiother Oncol. 2006 Jun;79(3):288-97. doi: 10.1016/j.radonc.2006.04.008. Epub 2006 May 26. Radiother Oncol. 2006. PMID: 16730088 - Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.
Bache M, Kappler M, Said HM, Staab A, Vordermark D. Bache M, et al. Curr Med Chem. 2008;15(4):322-38. doi: 10.2174/092986708783497391. Curr Med Chem. 2008. PMID: 18288988 Review.
Cited by
- Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.
Liu C, Lin Q, Yun Z. Liu C, et al. Radiat Res. 2015 May;183(5):487-96. doi: 10.1667/RR13959.1. Epub 2015 May 4. Radiat Res. 2015. PMID: 25938770 Free PMC article. Review. - Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Lin CM, Yu CF, Huang HY, Chen FH, Hong JH, Chiang CS. Lin CM, et al. Front Oncol. 2019 Apr 26;9:307. doi: 10.3389/fonc.2019.00307. eCollection 2019. Front Oncol. 2019. PMID: 31106146 Free PMC article. - Clinical biomarkers for hypoxia targeting.
Le QT, Courter D. Le QT, et al. Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9. Cancer Metastasis Rev. 2008. PMID: 18483785 Free PMC article. Review. - Hypoxia in microscopic tumors.
Li XF, O'Donoghue JA. Li XF, et al. Cancer Lett. 2008 Jun 18;264(2):172-80. doi: 10.1016/j.canlet.2008.02.037. Epub 2008 Apr 1. Cancer Lett. 2008. PMID: 18384940 Free PMC article. Review. - Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.
Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H. Yang R, et al. Cancer Res. 2017 Nov 15;77(22):6097-6108. doi: 10.1158/0008-5472.CAN-17-1018. Epub 2017 Sep 22. Cancer Res. 2017. PMID: 28939681 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources